Physician profile
John W Gilbert
NPI 1720051501
$3,991.93
in general payments reported to CMS, 2019-2025
10 companies · $46.32 in 2025
The $46.32 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $203 · 2021: $362 · 2022: $404 · 2023: $1,084 · 2024: $1,478 · 2025: $46.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,260 · Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,260.11 |
| Food and Beverage | $347.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integrity Implants INC. Dba Accelus | $1,443.19 | 2024 | |
| Nevro Corp. | $1,168.30 | 2019-2022 | |
| Spineology INC. | $1,083.92 | 2023 | Optimesh Expandable Interbody Fusion System |
| Zimmer Biomet Holdings, INC. | $85.17 | 2021 | |
| Medtronic USA, INC. | $71.49 | 2019-2020 | |
| Globus Medical, INC. | $46.32 | 2025 | Vyrsa V1 |
| Wenzel Spine, INC. | $34.44 | 2024 | Primalok Sp |
| Boston Scientific Corporation | $23.33 | 2019 | |
| Medtronic, INC. | $22.73 | 2021 | |
| Novo Nordisk INC | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.